RxDoctor Payments Data

Terry Green, NP

Adult Health · Oklahoma City, OKNPI 1083630115

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $5,735 of the $8,891 with a category attached, or 64.5%. 13 manufacturers reported payments, led by Gilead at 52.6% of the total. Reporting peaked in 2021 at $6,759 and has fallen 87.4% since, to $853 in 2025. Among adult health clinicians in OK with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$8,891in general payments, 2019–2025

Across 63 payments — averaging $141.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$5K
  • AbbVie$3K
  • Madrigal Pharmaceuticals$535
  • Intercept Pharmaceuticals, Inc.$347
  • Ipsen Biopharmaceuticals, Inc$237
  • Mallinckrodt Hospital Products Inc.$117
  • plus $205 from 7 others

What the payments were for

  • Consulting fees$6908%
  • Speaking & faculty fees$5,73565%
  • Food & beverage$2,46628%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,891 in reported general payments places this provider in the 95th percentile of 117 adult health providers in Oklahoma.

See all adult health providers in Oklahoma

Medicare billing

Part B allowed, 2024
$7,419
Medicare patients
97
Services billed
138

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EpclusaSofosbuvir/Velpatasvir39$938,605
XifaxanRifaximin13$43,819
Ursodiol16$1,084
Furosemide13$100
Spironolactone15$100
Carvedilol16$81

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadEpclusa$4,676$938,60539 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$40$43,81913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 117 adult health providers in Oklahoma.

Other adult health in Oklahoma City

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →